

1635
IY
PTO/SB/21 (01-08)

Approved for use through 01/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number
08/978,633

Filing Date
November 25, 1997

First Named Inventor
Rabbani

Art Unit
1635

Examiner Name
J. Angell

Attorney Docket Number
ENz53(D1)

ENCLOSURES (Check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment/Reply
 - After Final
 - Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Reply to Missing Parts/ Incomplete Application
 - Reply to Missing Parts under 37 CFR 1.52 or 1.53

- Drawing(s)
- Licensing-related Papers
- Petition
 - Petition to Convert to a Provisional Application
 - Power of Attorney, Revocation
 - Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s) _____
- Landscape Table on CD

Remarks

Please charge fee set forth in 37 CFR 1.17(p) to deposit acct no. 05-1135

- After Allowance Communication to TC
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please Identify below):
 - Information Disclosure Statement Transmittal Letter, 3 Foreign Patent Documents and 51 non-patent documents +fee (charge to deposit acct no. 05-1135).

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name
The Law Offices of Cheryl H. Agris, Ph.D., P.C.

Signature
Cheryl H. Agris

Printed name
Cheryl H. Agris

Date
January 9, 2008 Reg. No.
34,086

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature
Cheryl H. Agris

Typed or printed name
Cheryl H. Agris Date
January 9, 2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	08978633
Filing Date	1997-11-25
First Named Inventor	Rabbani
Art Unit	1635
Examiner Name	J. Angell
Attorney Docket Number	Enz-53-D1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith. -Please charge to acct no

- None

SIGNATURE

05-1135.


A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	<i>Cheryl H. Agus</i>	Date (YYYY-MM-DD)	2008-01-09
Name/Print	Cheryl H Agus	Registration Number	34086

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No.:ENZ53(D1)

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rabbani et al.

Application No.: 08/978,633 Group Art Unit: 1635

Filed: November 25, 1997 Examiner: J. Angell

For: **NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING
COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES**

Confirmation No.: 4639

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith further references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

Form PTO/SB08a lists US and foreign patent documents and non patent literature that have not been made of record. Some of these foreign patent documents and non-patent literature have been submitted previously. Those submitted herewith are listed below:

01/11/2008 EAYALEW1 00000046 051135 08978633

01 FC:1806 180.00 DA

Foreign Patents

WO9528494 1995-10-26 Overell et al.

WO9508635 1995-03-30 Craig et al.

WO9506129 1995-03-02 Craig et al.

Non-patent documents

VERMA Nature 389: 239-242. 1997

FISHER Neurobiology of Disease 4: 1-22. 1997

DATTA et al. Mol. Cell Biol. 16: 1085-1093. 1996

WANG et al., Proc. Natl. Acad. Sci. USA 92: 3318-3322. 1995

THIMME et al., Virology 211: 296-301. 1995

SUN et al. Proc. Natl. Acad. Sci. USA 92: 7272-7276. 1995

ROSSI, Trends Biotechnol. 13: 301-306. 1995

RAMIREZ et al., Virology 206: 57-68. 1995

PARDRIDGE et al., Proc. Natl. Acad. Sci. USA 92: 5592-5596. 1995

MILLER et al., FASEB J. 9: 190-199. 1995

LIMJOCO et al. Virology 208: 75-83. 1995

LAU et al., Hum Gene Ther. 6: 1145-1151. 1995

BINKLEY et al. Nucleic Acids Res. 23: 3198-3205. 1995

ALLY et al., J. Immunol. 155: 5404-5408. 1995

AGRAWAL et al., Biochem. Pharmacol. 50: 571-576. 1995

VIEILLARD et al. Proc. Natl. Acad. Sci. USA 91: 2689-2693. 1994

LEWIN in Genes V, pp 914-915. 1994

JUNKER et al. Antisense Res. Dev. 4: 165-172. 1994

GRUBER et al. J. Immunol. 152: 5368-5374. 1994

DE YOUNG et al. Biochemistry 33: 12127-12138. 1994

CROOKE, Antisense Res. and Development 4: 145-146. 1994

VLASSOV et al., FEBS Lett. 327: 271-274. 1993

LIEBER et al. Methods Enzymol. 217: 47-66. 1993

FISCHER et al. EMBO J. 12: 573-583. 1993

COX et al. *Advan. Enzyme Regul.* 33: 27-36. 1993
BALVAY et al. *BioEssays* 15: 165-169. 1993
ALLAWAY et al. *AIDS Res. Human Retroviruses* 9: 581-587. 1993
ZAIA et al., *Annals of the NY Acad Sci* 660: 95-106. 1992
TAKEDA et al., *Proc. Natl. Acad. Sci USA* 89: 8180-8184. 1992
IZANT in *Gene Regulation: Biology of Antisense RNA and DNA* pp 183-195. Raven Press, Ltd. New York 1992
DUMONTET et al. *La Revue de Medecine Intern.* 13: 460-464. 1992.
CHEN et al. in *Antisense Strategies*, *Annals NY Acad. Sci.* 660: 271-273. 1992

BURKLY et al., *J. Immunol.* 149: 1779-1787. 1992
PILCH et al. *Gene Expression* 1: 41-53. 1991
FARUQI et al., *Virology* 183: 764-768. 1991
YAMASHITA et al. *Agric. Biol. Chem.* 54: 2801-2809. 1990
FISCHER et al. *Science* 249: 786-790. 1990.
YOSHIMATSU et al. *Science* 244: 1346-1348. 1989
VOS et al. *Mol. Cell. Biol.* 9: 2897-2905. 1989
GATERMANN et al. *Mol. Cell Biol.* 9: 1526-1535. 1989
NEUMAN DE VEGVAR *Nucleic Acids Res.* 17: 9305-9318. 1989
BEBENEK et al. *J. Biol. Chem.* 264: 16948-16956. 1989
LEIBOLD et al. *Proc. Natl. Acad. Sci. USA* 85: 2171-2175. 1988
OLD et al., Blackwell Scientific Publications, London, 1986
DAVIS et al., Elsevier, NY 1986
✓ AGRAWAL et al. *Nucleic Acids Res.* 14: 6227-6245. 1986
PERBAL, John Wiley & Sons, New York, 1984
DUNN et al., *J. Mol. Biol.* 166: 477-535. 1983
MANIATIS et al., Cold Spring Harbor Laboratory Press, 1982
ANDERSON et al. *Nature* 290: 754-758. 1981
Definitions for "compound", "polymer", "monomer" on 2005-10-19 from
www.cancerweb.ncl.ac.uk

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The Information Disclosure Statement submitted herewith is being filed

[] after submitting the RCE but before any subsequent Office Action

[] before the mailing date of a first Office Action on the merits

[X] after the mailing date of a first Office Action on the merits. Please charge the fee of \$180 to deposit account no. 05-1135.

Respectfully submitted,

Date: 1/9/08

Cheryl H. Agris

Cheryl H. Agris, Reg. No. 34,086

(914) 712-0093